These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 32223318)

  • 1. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
    Bhatt DL; Eikelboom JW; Connolly SJ; Steg PG; Anand SS; Verma S; Branch KRH; Probstfield J; Bosch J; Shestakovska O; Szarek M; Maggioni AP; Widimský P; Avezum A; Diaz R; Lewis BS; Berkowitz SD; Fox KAA; Ryden L; Yusuf S;
    Circulation; 2020 Jun; 141(23):1841-1854. PubMed ID: 32223318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
    Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
    Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
    Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
    Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease.
    Steffel J; Eikelboom JW; Anand SS; Shestakovska O; Yusuf S; Fox KAA
    Circulation; 2020 Jul; 142(1):40-48. PubMed ID: 32436455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
    Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
    Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
    Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
    J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
    Guzik TJ; Ramasundarahettige C; Pogosova N; Lopez-Jaramillo P; Dyal L; Berkowitz SD; Muehlhofer E; Bhatt DL; Fox KAA; Yusuf S; Eikelboom JW
    J Am Coll Cardiol; 2021 Feb; 77(5):511-525. PubMed ID: 33538248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
    Eikelboom JW; Bhatt DL; Fox KAA; Bosch J; Connolly SJ; Anand SS; Avezum A; Berkowitz SD; Branch KRH; Dagenais GR; Félix C; Guzik TJ; Hart RG; Maggioni AP; Muehlhofer E; Sharma M; Shestakovska O; Yusuf S
    J Am Coll Cardiol; 2021 Jul; 78(1):14-23. PubMed ID: 34210409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
    Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
    JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
    Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP; Widimsky P; Berkowitz SD; Yusuf S; Connolly SJ; Eikelboom JW; Bosch J
    Eur J Prev Cardiol; 2020 Feb; 27(3):296-307. PubMed ID: 31615291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroke Outcomes in the COMPASS Trial.
    Sharma M; Hart RG; Connolly SJ; Bosch J; Shestakovska O; Ng KKH; Catanese L; Keltai K; Aboyans V; Alings M; Ha JW; Varigos J; Tonkin A; O'Donnell M; Bhatt DL; Fox K; Maggioni A; Berkowitz SD; Bruns NC; Yusuf S; Eikelboom JW
    Circulation; 2019 Feb; 139(9):1134-1145. PubMed ID: 30667279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
    Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
    Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
    Eikelboom JW; Connolly SJ; Bosch J; Dagenais GR; Hart RG; Shestakovska O; Diaz R; Alings M; Lonn EM; Anand SS; Widimsky P; Hori M; Avezum A; Piegas LS; Branch KRH; Probstfield J; Bhatt DL; Zhu J; Liang Y; Maggioni AP; Lopez-Jaramillo P; O'Donnell M; Kakkar AK; Fox KAA; Parkhomenko AN; Ertl G; Störk S; Keltai M; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Verhamme PB; Vinereanu D; Kim JH; Tonkin AM; Lewis BS; Felix C; Yusoff K; Steg PG; Metsarinne KP; Cook Bruns N; Misselwitz F; Chen E; Leong D; Yusuf S;
    N Engl J Med; 2017 Oct; 377(14):1319-1330. PubMed ID: 28844192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
    Bhagirath VC; Eikelboom JW; Anand SS
    Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
    Gaba P; Bhatt DL; Dagenais GR; Bosch J; Maggioni AP; Widimsky P; Leong D; Fox KAA; Yusuf S; Eikelboom JW;
    JAMA Netw Open; 2022 Nov; 5(11):e2243201. PubMed ID: 36409491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.
    Perera KS; Ng KKH; Nayar S; Catanese L; Dyal L; Sharma M; Connolly SJ; Yusuf S; Bosch J; Eikelboom JW; Hart RG
    JAMA Neurol; 2020 Jan; 77(1):43-48. PubMed ID: 31524941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
    Debus ES; Nehler MR; Govsyeyev N; Bauersachs RM; Anand SS; Patel MR; Fanelli F; Capell WH; Brackin T; Hinterreiter F; Krievins D; Nault P; Piffaretti G; Svetlikov A; Jaeger N; Hess CN; Sillesen HH; Conte M; Mills J; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP
    Circulation; 2021 Oct; 144(14):1104-1116. PubMed ID: 34380322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.